Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 370

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Open access
van der Heijde, Désirée, Cheng-Chung Wei, James, Dougados, Maxime, Mease, Philip, Deodhar, Atul, Maksymowych, Walter P, Van den Bosch, Filip, Sieper, Joachim, Tomita, Tetsuya, Landewé, Robert, Zhao, Fangyi, Krishnan, Eswar, Adams, David H., Pangallo, Beth, Carlier, Hilde, Churchill, Melvin, Flint, Kathleen, Gladstein, Geoffrey, Greenwald, Maria, Howell, Mary, Ince, Akgun, Kaine, Jeffrey, Mehta, Daksha, Peters, Eric, Querubin, Roel, Reveille, John, Roseff, Richard, Diegel, Roger, Thai, Christine, Bessette, Louis, Morin, Frederic, Rahman, Proton, Barrera Rodriguez, Aaron Alejandro, Cons-Molina, Fidencio, Duran Barragan, Sergio, Skinner, Cassandra, Pacheco Tena, Cesar, Ramos Remus, Cesar, Rizo Rodriguez, Juan Cruz, Hong, Seung-Jae, Lee, Yeon-Ah, Ju, Ji Hyeon, Kang, Seong Wook, Kim, Tae-Hwan, Lee, Chang Keun, Lee, Eun Bong, Lee, Sang Heon, Park, Min-Chan, Shin, Kichul, Lee, Sang-Hoon, Chen, Hung-An, Chen, Ying-Chou, Hsieh, Song-Chou, Lan, Joung-Liang, Dvorak, Zdenek, Moravcova, Radka, Malcova, Martina, Taniguchi, Yoshinori, Kishimoto, Mitsumasa, Tada, Kurisu, Dobashi, Hiroaki, Inui, Kentaro, Ueki, Yukitaka, Matsumoto, Yoshifuji, Koyama, Yoshinobu, Hatta, Kazuhiro, Atsumi, Tatsuya, Goto, Hitoshi, Matsui, Kiyoshi, Takakubo, Yuya, Neeck, Gunther, Poddubnyy, Denis, Rubbert-Roth, Andrea, Szymanska, Malgorzata, Blicharski, Tomasz, Dudek, Anna, Racewicz, Artur, Wojciechowski, Rafal, van de Sande, Marleen, Griep, Ed, Nurmohamed, Mike, Matsievskaya, Galina, Shmidt, Evgeniya, Stanislav, Marina, Yakushin, Sergey, Ershova, Olga, Rebrov, Andrey, Balazs, Tibor, Cseuz, Regina, Drescher, Edit, Poor, Gyula·2018·The Lancet

Abstract

BACKGROUND Biological disease-modifying anti-rheumatic drugs (bDMARDs) are recommended for radiographic axial spondyloarthritis, otherwise known as ankylosing spondylitis, when conventional therapies are not effective. We report efficacy and safety data on ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A (IL-17A), in patients with radiographic axial spondyloarthritis who have not previously been treated with bDMARDs. METHODS In this phase 3, randomised, double-blind, placebo-controlled superiority study of ixekizumab, adult patients with inadequate response or intolerance to non-steroidal anti-inflammatory drugs, an established diagnosis of radiographic axial spondyloarthritis, radiographic sacroiliitis centrally defined by modified New York criteria, and at least one spondyloarthritis feature according to the Assessment of SpondyloArthritis international Society (ASAS) criteria, were recruited from 84 sites (12 countries) in Europe, Asia, and North America. By use of a computer-generated random sequence, patients were randomly assigned (1:1:1:1) to 80 mg subcutaneous ixekizumab every two (Q2W) or four (Q4W) weeks, 40 mg adalimumab Q2W (active reference group), or placebo. The primary objective was to compare the proportion of patients achieving an ASAS40 response, a composite measure of clinical improvement in axial spondyloarthritis, at week 16 for both ixekizumab treatment groups versus the placebo group. The adalimumab reference group was included as an in-study active reference for comparison with placebo to provide additional context to interpretation of the ixekizumab study results. FINDINGS Between June 20, 2016, and Aug 22, 2017, 341 patients were randomly assigned to either the placebo group (n=87), adalimumab group (n=90), ixekizumab Q2W (n=83), or ixekizumab Q4W (n=81). At week 16, compared with placebo (16 [18%] of 87), more patients achieved ASAS40 with ixekizumab Q2W (43 [52%] of 83; p<0·0001), ixekizumab Q4W (39 [48%] of 81; p<0·0001), and adalimumab (32 [36%] of 90; p=0·0053). One serious infection occurred in each of the ixekizumab Q2W (1%), ixekizumab Q4W (1%), and adalimumab (1%) groups; none were reported with placebo. One (1%) Candida infection occurred in the adalimumab group and one (1%) patient receiving ixekizumab Q2W was adjudicated as having probable Crohn's disease. No treatment-emergent opportunistic infections, malignancies, or deaths occurred. INTERPRETATION Each dosing regimen of ixekizumab was superior to placebo for improving radiographic axial spondyloarthritis signs and symptoms in patients not previously treated with bDMARDs; the safety profile was consistent with previous indications of ixekizumab. FUNDING Eli Lilly and Company.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(18)31946-9

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 370

Metadata

Authors
van der Heijde, D., Cheng-Chung Wei, J., Dougados, M., Mease, P., Deodhar, A., Maksymowych, W. P., Van den Bosch, F., Sieper, J., Tomita, T., Landewé, R., Zhao, F., Krishnan, E., Adams, D. H., Pangallo, B., Carlier, H., Churchill, M., Flint, K., Gladstein, G., Greenwald, M., Howell, M., Ince, A., Kaine, J., Mehta, D., Peters, E., Querubin, R., Reveille, J., Roseff, R., Diegel, R., Thai, C., Bessette, L., Morin, F., Rahman, P., Barrera Rodriguez, A. A., Cons-Molina, F., Duran Barragan, S., Skinner, C., Pacheco Tena, C., Ramos Remus, C., Rizo Rodriguez, J. C., Hong, S.-J., Lee, Y.-A., Ju, J. H., Kang, S. W., Kim, T.-H., Lee, C. K., Lee, E. B., Lee, S. H., Park, M.-C., Shin, K., Lee, S.-H., Chen, H.-A., Chen, Y.-C., Hsieh, S.-C., Lan, J.-L., Dvorak, Z., Moravcova, R., Malcova, M., Taniguchi, Y., Kishimoto, M., Tada, K., Dobashi, H., Inui, K., Ueki, Y., Matsumoto, Y., Koyama, Y., Hatta, K., Atsumi, T., Goto, H., Matsui, K., Takakubo, Y., Neeck, G., Poddubnyy, D., Rubbert-Roth, A., Szymanska, M., Blicharski, T., Dudek, A., Racewicz, A., Wojciechowski, R., van de Sande, M., Griep, E., Nurmohamed, M., Matsievskaya, G., Shmidt, E., Stanislav, M., Yakushin, S., Ershova, O., Rebrov, A., Balazs, T., Cseuz, R., Drescher, E., & Poor, G.
Venue
The Lancet
Publisher
Elsevier BV
Published
2018-12
Volume
392
Issue
10163
Pages
2441-2451
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2897890026
Cited by
370
References
25
FWCI
32.65
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(18)31946-9
The paper
van der Heijde, D., Cheng-Chung Wei, J., Dougados, M., Mease, P., Deodhar, A., Maksymowych, W. P., Van den Bosch, F., Sieper, J., Tomita, T., Landewé, R., Zhao, F., Krishnan, E., Adams, D. H., Pangallo, B., Carlier, H., Churchill, M., Flint, K., Gladstein, G., Greenwald, M., . . . Poor, G. (2018). Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(18)31946-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.